Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 19Triple Negative Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Neoplasm Metastasis 3Brain Neoplasms 3Salivary Gland Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Metastatic Urothelial Cancer 1Laryngeal Neoplasms 1Klatskin Tumor 1Hypopharyngeal Neoplasms 1HER2-negative Breast Cancer 1Glioblastoma 1

Interventions

apatinib 3vistusertib 2olaparib 2camrelizumab 2atezolizumab 2Ipilimumab 2Everolimus 2trametinib 1toripalimab 1tilsotolimod 1tazemetostat 1tazarotene 1spartalizumab 1seviteronel 1sargramostim 1sacituzumab govitecan 1rucaparib 1roniciclib 1romiplostim 1pyrotinib 1phosphorylethanolamine 1pemigatinib 1pembrolizumab 1pazopanib 1palbociclib 1niraparib 1magrolimab 1lenvatinib 1irinotecan sucrosofate 1famitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumor × sacituzumab govitecan × Clear all
NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Gilead Sciences

Phase 2 Active not recruiting
53 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡